[6/26]
WHO ±Û·Î¹ú COVID-19 ¿ªÇÐ µ¿Çâ
(COVID-19 Global Epidemiological Update )
Coronavirus Disease 2019 (COVID-19) µ¿Çâ Highlights
¼¼°èº¸°Ç±â±¸ COVID-19 Highlights Situation Report - 157
ÁÖ¿ä ±¹°¡º° COVID-19 È®ÁøÀÚ, Ä¡¸í·ü ¹× ¿ÏÄ¡À²(2020.0626)
ÇöÀç Àü¼¼°èÀûÀ¸·Î 214°³±¹¿¡¼ COVID-19·Î ÀÎÇÑ È®ÁøÀÚ´Â 9,296,202 cases (167,056), »ç¸ÁÀÚ 479,133¸í (5,336)À¸·Î ÇöÀç±îÁö Ä¡¸íÀ²(CFR)Àº 5.15%¸¦ ³ªÅ¸³»°í ÀÖ´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ ÀÇÇÑ ÁÖ¿ä Áö¿ªº° È®ÁøÀÚ ¹× Ä¡¸í·ü(CFR)Àº ¾Æ·¡¿Í °°´Ù.
Ç¥ 1 ) ¼¼°è Áö¿ªº° COVID-10 È®ÁøÀÚ, Ä¡¸í·ü (WHO Situation Report-157)
[Globally ÃÑ È®ÁøÀÚ 9,296,202¸í(½Å±Ô 167,056¸í), »ç¸ÁÀÚ 479,133¸í(½Å±Ô 5,336¸í) ]
±¸ºÐ
|
À¯·´
|
¾Æ¸Þ¸®Ä«
|
µ¿ºÎÁöÁßÇØ
|
¼ÅÂÆò¾ç
|
µ¿³²¾Æ½Ã¾Æ
|
¾ÆÇÁ¸®Ä«
|
È®ÁøÀÚ(¸í)
|
2,600,590
|
248,558
|
969,656
|
209,215
|
663,308
|
248,558
|
»ç¸ÁÀÚ(¸í)
|
194,972
|
5,441
|
22,003
|
7,383
|
19,156
|
5,441
|
Ä¡¸í·ü(CFR)
|
7.49%
|
2.19%
|
2.27%
|
3.53%
|
2.29%
|
2.19%
|
±×¸² 1) COVID-19 È®Áø ±¹°¡ ¹× Áö¿ªº° È®Áø »ç·Ê(2020³â6¿ù26ÀÏÀÚ WHO º¸°í)
Source: WHO Coronavirus disease 2019 (COVID-19) Situation Report -157 [¹Ù·Î°¡±â]
Ç¥ 2) ±¹°¡ ¹× Áö¿ªº° COVID-19 È®Áø ÇöȲ(2020³â6¿ù26ÀÏÀÚ WHO º¸°í)
Source: WHO Coronavirus disease 2019 (COVID-19) Situation Report 157
±×¸² 3) COVID-19 È®Áø ¿ªÇа(³¯Â¥º°, Áö¿ªº° 2020³â 6¿ù26ÀÏÀÚ)
Source: WHO Coronavirus disease 2019 (COVID-19) Situation Report 157 [¹Ù·Î°¡±â]
[ÃֽŠ¿¬±¸µ¿Çâ] Coronavirus 2019 (COVID-19)] Highlights
COVID-19 ¸é¿ª¹ÝÀÀ -- Ç×ü 2°³¿ù°£ ¾ÈÁ¤ÀûÀ¸·Î Áö¼Ó
(COVID-19 immune response may remain stable for two months after diagnosis)
¿µ±¹ ·±´ø ¼¼ÀÎÆ® Á¶Áö ´ëÇаú º´¿ø(St George's, University of London & St George's University Hospitals NHS Foundation Trust)°ú ¸®¹öÇ® ÀÇÇÐ ¿¬±¸ÆÀ(Liverpool School of Tropical Medicine, Mologic Ltd. and Institut Pasteur de Dakar, Sénégal)ÀÌ Äڷγª-19 È®ÁøÀÚ 177¸íÀ» ´ë»óÀ¸·Î ÁøÇàÇÑ Ç×ü°Ë»ç °á°ú, COVID-19 °¨¿° Áø´Ü ÈÄ °ÅÀÇ 2 °³¿ùÀÌ Áö³ª¼ °¨¿°µÈ »ó´ç ¼öÀÇ È¯ÀÚÇ÷¾×¿¡¼ Ç×ü°¡ ¾ÈÁ¤ÀûÀ¸·Î À¯ÁöµÈ´Ù´Â º¸°í°¡ ¹ßÇ¥µÇ¾ú´Ù. [»ó¼¼º¸±â]
[NEJM Ãֽŵ¿Çâ] COVID-19 ÈæÀΰú ¹éÀÎȯÀÚÀÇ ÀÔ¿øÀ²°ú »ç¸Á·ü ºñ±³ (Hospitalization and Mortality among Black Patients and White Patients with Covid-19)
·çÀÌÁö¾Ö³ªÁÖÀÇ ´ë±Ô¸ð ÄÚȣƮ¿¬±¸¸¦ ÅëÇÏ¿© Covid-19·Î ÀÔ¿ø ÇÑ È¯ÀÚÀÇ 76.9 %¿Í »ç¸Á ȯÀÚÀÇ 70.6 %´Â ÈæÀÎÀ¸·Î ³ªÅ¸³µÀ¸³ª, ÀÔ¿ø ½Ã »çȸÀα¸ Åë°èÇÐÀû ¹× ÀÓ»óƯ¼ºÀÇ Â÷À̸¦ Á¶Á¤ÇÑ ÈÄ, ÈæÀÎ ÀÎÁ¾Àº ¹éÀÎ ÀÎÁ¾º¸´Ù º´¿ø ³» »ç¸Á·üÀÌ ³ôÁö ¾ÊÀ½À¸·Î ³ªÅ¸³µ´Ù. [»ó¼¼º¸±â]
NIH- Remdesivir (·½µ¥½Ãºñ¸£) COVID-19 Ä¡·áÁ¦·Î ½ÂÀÎ
¹Ì±¹ ±¹¸³º¸°Ç¿¬±¸¿ø(NIH)ÀÌ ¼öÇàÇÑ Ç×¹ÙÀÌ·¯½º ·½µ¥½Ãºñ¾î(remdesivir) ÀÓ»ó½ÃÇ迬±¸ °á°ú°¡ NEJM (New England Journal of Medicine.)À» ÅëÇØ ¹ßÇ¥µÇ¾ú´Ù. (https://www.nejm.org/doi/full/10.1056/NEJMoa2007764?query=featured_home)
ÀÌ °á°ú¸¦ ±Ù°Å·Î 5¿ù 1ÀÏ¿¡ ¹Ì±¹ FDA(½Ä¾àó)´Â ·½µ¥½Ãºñ¾î¸¦ ¡¸ÁßÁõ¡¹È¯ÀÚ(»ê¼ÒÆ÷ȵµ <94%, »ê¼Ò Ä¡·á ÇÊ¿ä)¿¡°Ô ±ä±Þ»ç¿ëÇã°¡¸¦ ½ÂÀÎÇÏ¿´À¸¸ç, ÀÌÁ¦ ·½µ¥½Ãºñ¾î°¡ COVID-19ÀÇ Ç¥ÁØ Ä¡·áÁ¦·Î »ç¿ëÇã°¡µÇ¾ú´Ù. [»ó¼¼º¸±â]
[±¹³»Ç÷ÀåÄ¡·á¼º°ø] COVID-19: ¿ÏÄ¡ÀÚ Ç÷ÀåÄ¡·á(Convalescent Plasma)
±¹³» ¼¼ºê¶õ½ºº´¿ø ¿¬±¸ÆÀÀº ¿ÏÄ¡ÀÚ Ç÷Àå(Convalescent Plasma) Ä¡·á¹æ¹ýÀ¸·Î ÀÓ»ó¿¡¼ Coronavirus disease 2019 (COVID-19)ÀÇ ¿ÏÄ¡ »ç·Ê¸¦ º¸°íÇß´Ù. ÀÌ°ÍÀº Çѱ¹¿¡¼ COVID-19¿¡ ´ëÇÑ ¿ÏÄ¡ÀÚ Ç÷Àå Ä¡·á¿¡ ´ëÇÑ Ã¹ ¹ø° ÀÓ»ó ¿ÏÄ¡»ç·ÊÀÌ´Ù. [»ó¼¼º¸±â]
COVID-19 Ä¡·áÁ¦°³¹ß ±Û·Î¹ú Àӻ󿬱¸ ÇÁ·ÎÁ§Æ®ÇöȲ
½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ(Äڷγª19) Ä¡·áÁ¦ °³¹ßÀ» À§ÇØ Àü¼¼°è°¡ ³ë·ÂÇÏ°í ÀÖ´Â °¡¿îµ¥, ÇöÀç Äڷγª 19 Ä¡·áÁ¦ °³¹ß°ú °ü·Ã ±¹Á¦ÀûÀ¸·Î Àӻ󿬱¸°¡ 335,815°ÇÀÌ ÁøÇà Áß¿¡ ÀÖ´Ù(2020³â 4¿ù 13ÀÏÀÚ µî·ÏÇöȲ). ¹Ì±¹ ±¹¸³º¸°Ç¿ø NIH ClinicalTrials.gov¿¡ µî·ÏµÇ¾î ÁøÇàÇÏ°í ÀÖ´Â COVID-19 °ü·Ã Àӻ󿬱¸´Â 300¿©°Ç ÀÌ»óÀÌ ÁøÇà Áß¿¡ ÀÖÀ¸¸ç, ¼¼°èº¸°Ç±â±¸(WHO)±¹Á¦Àӻ󿬱¸µî·Ï Ç÷§Æû(World Health Organization's International Clinical Trials Registry Platform, WHO ICTRP)¿¡¼´Â 590°ÇÀÇ ÇÁ·ÎÁ§Æ®°¡ ÇöÀç Àӻ󿬱¸ Áß¿¡ ÀÖ´Ù. [»ó¼¼º¸±â]
NEJM COVID-19 º¸°í [½ÉÇ÷°üÁúȯ ¾à¹°Ä¡·á, »ç¸Á·ü ¿äÀÎ ¿¬±¸(Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19): Angiotensin-converting–enzyme (ACE) inhibitors & angiotensin-receptor blockers (ARBs)]
º» ¿¬±¸´Â The New England Journal of Medicine 2020³â 5¿ù 1ÀÏÀÚ ¹ßÇ¥µÈ COVID-19 ½ÉÇ÷°üÁúȯÀÇ ¾à¹°Ä¡·á- Angiotensin-converting–enzyme (ACE) inhibitors¿Í Angiotensin-receptor blockers (ARBs) »ç¿ë¿¡ ´ëÇÑ ÀáÀçÀû À§Çؼº Æò°¡¿Í »ç¸Á·ü °ü·Ã¿äÀÎ ¿¬±¸ÀÌ´Ù.
º´¿ø ³» »ç¸ÁÀ² Áõ°¡¿Í °ü·ÃÀÖ´Â µ¶¸³¿äÀεéÀº ¾Æ·¡¿Í °°´Ù.
1. 65¼¼ ÀÌ»ó ¿¬·É( (mortality of 10.0%, vs. 4.9% among those ≤65 years of age; odds ratio, 1.93; 95% confidence interval [CI], 1.60 to 2.41) (65 ¼¼ ¹Ì¸¸ÀÇ »ç¸Á·üÀº 10.0 %, »ç¸Á·üÀº 4.9 %)
2. °ü»óµ¿¸Æ Áúȯ(10.2%, vs. 5.2% among those without disease; OR, 2.70; 95% CI, 2.08 to 3.51)
3. ½ÉºÎÀü(15.3%, vs. 5.6% among those without heart failure; OR 2.48; 95% CI, 1.62 to 3.79)
4. ½ÉÀåºÎÁ¤¸Æ(11.5%, vs. 5.6% among those without arrhythmia; OR, 1.95; 95% CI, 1.33 to 2.86)
5. ¸¸¼ºÆó¼â¼ºÆóÁúȯ(14.2%, vs. 5.6% among those without disease; OR, 2.96; 95% CI, 2.00 to 4.40)
6. ÇöÀç Èí¿¬(9.4%, vs. 5.6% among former smokers or nonsmokers; OR, 1.79; 95% CI, 1.29 to 2.47)
¾à¹°Ä¡·á¿Í »ç¸Á·ü°úÀÇ °ü·ÃÀ» ºÐ¼®ÇÑ °á°ú, ACE inhibitors (2.1% vs. 6.1%; OR, 0.33; 95% CI, 0.20 to 0.54) »ç¿ëÀ̳ª, ARB(6.8% vs. 5.7%; OR, 1.23; 95% CI, 0.87 to 1.74) ¾à¹°Ä¡·á´Â º´¿ø³»¿¡¼ »ç¸ÁÀ§ÇèÀ» Áõ°¡½ÃÅ°´Â °Í°ú °ü·ÃÀÌ ¾ø´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù. [¿ø¹®º¸±â]
COVID-19: ÁßÁõ ¼ºÀÎȯÀÚ ICU ÆÐÇ÷Áõ °¡À̵å¶óÀÎ
ÁßÁõ±Þ¼ºÈ£Èí±âÁõÈıºÀ» ¾ß±âÇÏ´Â SARS-CoV-2´Â Àü¼¼°èÀûÀ¸·Î ±Þ¼ÓÇÏ°Ô È®»êµÇ°í ÀÖÀ¸¸ç ¼ö¸¹Àº »ç¶÷µéÀÇ »ý¸íÀ» À§ÇùÇÏ°í ÀÖ´Ù. À̵éÀ» µ¹º¸´Â º¸°ÇÀÇ·áÀεé°ú ÀÓ»óÀǻ縦 À§ÇÑ ±ä±ÞÇÑ °¡À̵å¶óÀÎ °³¹ßÀÌ ÇÊ¿äÇÏ´Ù. COVID-19·Î ÀÎÇÑ ÆÐÇ÷Áõ °ü¸® ÁöħÀ» À§ÇØ ±¸¼ºµÈ ÆгÎÀº 54°³ÀÇ Áø¼ú¹®À» ¸¸µé¾ú°í ÀÌÁß¿¡¼ 4°¡Áö º£½ºÆ® ½Ç¹«°¡À̵å¶óÀΰú 9°¡Áö °·ÂÇÑ ±Ç°í»çÇ×°ú, 35°¡Áö Áõ°Å°¡ ºÎÁ·ÇÑ Á¦¾ÈµéÀº ¹ßÇ¥Çß´Ù. [´õº¸±â]
Ç¥ 3) Coronavirus disease (COVID-19) ÃֽŠÇмúÁ¤º¸ »çÀÌÆ® ¹Ù·Î°¡±â
Ç¥4) Coronavirus disease (COVID-19) ±¹³» ¹× ±¹¿Ü ÃÖ±Ù ¾÷µ¥ÀÌÆ® Á¤º¸ ¹Ù·Î°¡±â
ÀÇ°úÇבּ¸Á¤º¸¼¾ÅÍ Á¦°ø
References
WHO, Coronavirus, [¹Ù·Î°¡±â]
WHO, Coronavirus disease 2019 (COVID-19) Situation Report 157 (June 26, 2020) [¹Ù·Î°¡±â]
Hospitalization and Mortality among Black Patients and White Patients with Covid-19 (June 25, 2020). N Engl J Med 2020; 382:2534-2543. DOI: 10.1056/NEJMsa2011686
J Beigel, et al. Remdesivir for the Treatment of COVID-19 – A Preliminary Report. The New England Journal of Medicine. DOI: 10.1056/NEJMoa2007764 (2020).
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 (May 01, 2020). The New England Journal of Medicine [¹Ù·Î°¡±â]
Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults With Coronavirus Disease 2019 (COVID-19) [¿ø¹®º¸±â]
WHO Officials Discuss the Weather Question (March 05, 2020) [¹Ù·Î°¡±â]
Will Warm Weather Curb Coronavirus? What the Experts Say, Ari Altstedter & John Lauerman (March 12, 2020), Bloomberg Quicktake [¹Ù·Î°¡±â]
Revised U.S. Surveillance Case Definition for Severe Acute Respiratory Syndrome (SARS) and Update on SARS Cases --- United States and Worldwide, December 2003 [¹Ù·Î°¡±â]
JAMA COVID-19 Resource Center, Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72?314 Cases From the Chinese Center for Disease Control and Prevention JAMA. Published online February 24, 2020. [¹Ù·Î°¡±â]
¸Þ¸£½º (Middle East Respiratory Syndrome Coronavirus: MERS) Áúº´°ü¸®º»ºÎ [¹Ù·Î°¡±â]